Electroretinogram Changes in a Pediatric Population With Epilepsy: Is Vigabatrin Acting Alone?

Abstract

Vigabatrin, a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), is widely used as initial monotherapy in infantile spasms and add on therapy in partial onset seizures. Vigabatrin is associated with retinal toxicity causing constriction of the visual field. Our aim was to assess what effect add-on antiepileptic drug therapy has on the incidence of retinal toxicity in patients being treated with vigabatrin. Medication dosages, duration of treatment, and electroretinogram results were examined in a single center retrospective study. Retinal toxicity was detected in 18 of 160 patients (11.25%) over a 10-year period. A total of 14 (77%) were in the group treated with additional antiepileptic drugs, the other 4 received vigabatrin as monotherapy. We detected a significantly higher percentage of toxicity in the group of patients treated with vigabatrin and additional antiepileptic drugs. Our numbers were not sufficient to detect which drug or combination of drugs might be associated with higher risk.